Quick Answer
KALA BIO, Inc. reported Long Term Debt of $20.10 million for the year ending 2024.
- KALA BIO, Inc. showed a decrease of -41.2% in Long Term Debt from 2023 to 2024.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $7.49 million | Q3 2017: $13.63 million | Q1 2018: $19.75 million | Q2 2018: $18.10 million | Q3 2018: $16.46 million | Q1 2019: $70.46 million | Q2 2019: $70.69 million | Q3 2019: $70.94 million | Q1 2020: $71.44 million | Q2 2020: $71.70 million | Q3 2020: $71.97 million | Q1 2021: $72.52 million | Q2 2021: $78.06 million | Q3 2021: $78.49 million | Q1 2022: $79.36 million | Q2 2022: $79.80 million | Q3 2022: $42.64 million | Q1 2023: $33.27 million | Q2 2023: $33.57 million | Q3 2023: $33.88 million | Q1 2024: $28.51 million | Q2 2024: $22.83 million | Q3 2024: $17.16 million | Q4 2024: $20.10 million | Q1 2025: $15.12 million | Q2 2025: $18.79 million.
- Over the full 9 years of available data (2016 to 2024), KALA BIO, Inc.'s Long Term Debt has grown by 120.9%.
- Historical annual values: Fiscal year 2024: $20.10 million | Fiscal year 2023: $34.19 million | Fiscal year 2022: $37.94 million | Fiscal year 2021: $78.93 million | Fiscal year 2020: $72.24 million | Fiscal year 2019: $71.18 million | Fiscal year 2018: $70.23 million | Fiscal year 2017: $11.99 million | Fiscal year 2016: $9.10 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: